Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovarian Cancer:

Inclusion Criteria:

• Patient ≥ 18 years old

• ECOG 0-2

• Histologically proven epithelial ovarian carcinoma

• FIGO stage ≥ IIB

• Patient candidate for first line chemotherapy treatment (alone, neoadjuvant oradjuvant)

• Patient affiliated to an appropriate social security system

• Patient who has signed informed consent obtained before any trial related activities

Exclusion Criteria:

• Patient with an active implantable medical device or any other implanted electronicor electrical device (pacemaker, defibrillator, etc.)

• Dermatological problems in the area where stimulation electrodes are applied

• Recent history (<2 years) of epileptic seizures

• Proven severe cardiovascular disease (such as known FEV <40%, severe valvulpathy...)or HRV analysis not possible (such as uncontrolled atrial fibrillation)

• Serious ear pathology

• Documented vegetative neuropathy

• Unusual morphology of the left ear which does not allow the use of the device

• Patient with a cochlear implant near to the stimulation site

• Impaired cognitive abilities

• Concurrent other malignancy (except for appropriately treated in-situ cervixcarcinoma and non-melanoma skin carcinoma)

• Pregnant or breastfeeding woman

• Simultaneous participation in another clinical study that may compromise the conductof this study.

• Patient assessed by the investigator to be unable or unwilling to comply with therequirements of the protocol

• Patient deprived of liberty or placed under the authority of a tutor